Evidence map›Paper›PMID 30784598›Full record

ArticleCell reports2019

Mass Cytometry Analysis Reveals that Specific Intratumoral CD4

Zhi-Zhang Yang, Hyo Jin Kim, Jose C Villasboas, Tammy Price-Troska, Shahrzad Jalali, Hongyan Wu, Rebecca A Luchtel, Mei-Yin C Polley, Anne J Novak, Stephen M Ansell

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
46citing papers in PubMed, 1 pooled it
8.2field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

46 citing papers in PubMed, 1 synthesis or guideline pooled it, 78 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. T-cell phenotype including CD57Blood cancer journal · 2023
    Article
  15. Article
  16. Article
  17. Advances in the multi-omics landscape of follicular lymphoma.International journal of biological sciences · 2023
    Review
  18. Biology of follicular lymphoma: insights and windows of clinical opportunity.Hematology. American Society of Hematology. Education Program · 2022
    Article
  19. Phenotype, Function, and Clinical Significance of CD26+ and CD161+Tregs in Splenic Marginal Zone Lymphoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2022
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 2 countries.

Zhi-Zhang YangDivision of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN, USA. Electronic address: yang.zhizhang@mayo.edu.
Hyo Jin KimDivision of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN, USA.
Jose C VillasboasDivision of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN, USA.
Tammy Price-TroskaDivision of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN, USA.
Shahrzad JalaliDivision of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN, USA.
Hongyan WuDepartment of Immunology, Medical College, China Three Gorges University, Yichang, Hubei, China.
Rebecca A LuchtelDivision of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN, USA.
Mei-Yin C PolleyDivision of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN, USA.
Anne J NovakDivision of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN, USA.
Stephen M AnsellDivision of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN, USA. Electronic address: ansell.stephen@mayo.edu.
Mayo Clinic in Arizona · USChina Three Gorges University · CN

Funding

The Role of Monocytes in non-Hodgkin LymphomaP50CA097274 · NCI · UNIVERSITY OF IOWA · PI WEINER, GEORGE J. · 2002 to 2021
$45.7M
NCI NIH HHS P50 CA097274
6 · The paper itself

Abstract

Follicular lymphoma (FL) is an indolent B cell malignancy characterized by an extensive but poorly functional T cell infiltrate in the tumor microenvironment. Using mass cytometry, we identified at least 12 subsets of intratumoral CD4

Indexed as

Tumor MicroenvironmentAdultAgedAged, 80 and overBiomarkers, TumorCD28 AntigensCD4-Positive T-LymphocytesCell Line, TumorCells, CulturedFemaleHumansLymphoma, FollicularMaleMiddle AgedProgrammed Cell Death 1 ReceptorTumor Necrosis Factor Receptor Superfamily, Member 7Biomarkers, TumorCD28 AntigensProgrammed Cell Death 1 ReceptorTumor Necrosis Factor Receptor Superfamily, Member 7CD27CD4(+)CD25(+) regulatory T cellsco-stimulatory receptorCyTOFfollicular lymphomaimmune signatureintratumoral CD4(+) T cellmass cytometrypatient survivalPD-1

Identifiers

PMID30784598
PMCPMC6402596
OpenAlexW2917986195

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.